Allergan’s Inamed Purchase Delayed; Reloxin Will Go To Medicis
This article was originally published in The Gray Sheet
Executive Summary
Allergan was forced to push back its $3.2 bil. purchase of Inamed after failing to obtain the requisite amount of stock from Inamed shareholders